Gentlemen! We are all afraid of prostate cancer, are we not? And all the more so because the doctor could recommend the ultimate remedy castration! But even that may not be enough. Some cancers are resistant to castration.
But now there is hope, thanks to MDV3100 a drug that has been shown to extend the life of prostate sufferers. It's the lead product of Medivation (Nasdaq: MDVN) which has seen its share price quadruple over the last year.
This is the type of medical breakthrough that's driving a new bull market in biotech. The key Nasdaq Biotechnology Index, which already outperformed the broader market over the previous three years, has gone into overdrive adding 15% since the start of January.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
As you may know, I have talked about biotech before. I mentioned the high risks and the scintillating rewards.
I firmly believe that this will be the most exciting story of 2012. I mean you only have to look at the scale of the investment being pumped into the industry right now.
The big players are locked and loaded for biotech
Most of us know very little about biotechnology. Maybe we understand that it means the manipulation of living things to serve our own purposes. Maybe we know that much of what goes on under the heading of biotechnology relates to medicine. But few of us could go much further than that.
This is what smart investors like. They love the idea of getting in to a hot new story while others are still struggling to get their heads around it. The typical bull market sees professional investors get in early, and the private punters arriving at the party long after the best of the fun.
Right now, there are plenty of signs that professional investors are backing biotech. In 2011 venture capitalists invested $28.4 billion in the biotech sector, a 22% increase over the previous year. Now big new funds such as Flagship Ventures $270m life sciences vehicle are gathering ammunition to fire at biotechnology.
Key for any stock market theme is that it must have firm foundations. The natural resources theme was not a fantasy. It was based on rapidly growing demand meeting limited supply. The same could be said of biotechnology.
Biotech is needed now more than ever
The population is living longer, and the conditions which were once written off as mere old age' now demand treatment. The result is a massive increase in demand for new therapies. Meanwhile the major pharmaceutical companies have seen diminishing returns from their research budgets. With regulatory authorities, headed by the all-powerful US FDA, taking an ever more cautious approach to approvals, the supply of new therapies has simply not met the demand despite some notable successes in areas such as AIDs and smallpox.
This supply and demand imbalance is driving another key area for biotechnology research. Last week, I met Sir Ben Gill, former president of the National Farmers Union, and now chairman ofEden Research(PLUS: EDE). Eden uses naturally occurring compounds called terpenes to boost the defence mechanisms of food plants, and Sir Ben kicked off our meeting with a ten minute lecture on the world's impending food shortage.
These trends are fundamental and will not change. But the sudden upsurge in biotechnology shares reflects more than just this. There are signs that the pace of change is accelerating. The number of new drug compounds approved last year was the highest for some time.
Western governments don't want to be muscled out
Healthcare is a huge burden, but a 1% reduction in mortality from cancer alone would, according to University of Chicago economists Kevin Murphy and Robert Topel, have a present value to the USA of nearly $500bn. A complete cure would be worth about $50trn.
Western governments want to support biotechnology, especially as China, India and Russia are muscling in on the global market. So now a record number of trials are in progress, both in the clinic for human therapies and in fields and greenhouses for bio-engineered plants.
As big pharma edges closer to the patent cliff' it is stepping up the hunt for promising external research projects and it is prepared to pay sums that transform small biotech research companies overnight. An example is this year's $2.5 billion acquisition of Inhibitex (NASDAQ: INHX) by Bristol-Myers Squibb. The former's share price has gone from $4 to $26 since the autumn.
Where will the next bonanza come from? There is no shortage of candidates. In the US alone, there are more than 900 biotechnology products in development, with more than one-third aimed at cancer and related conditions and more than 20% targeting infectious diseases. It's almost guaranteed that amongst these biotechnology pioneers there'll be some major stock market winners.
You won't want to miss this
I am so confident in the biotechnology sector that I have dedicated a new newsletter to the industry. This letter will radically change the way you invest this year.
This article is taken from Tom Bulford's free twice-weekly small-cap investment email The Penny Sleuth. Sign up to The Penny Sleuth here.
Information in Penny Sleuth is for general information only and is not intended to be relied upon by individual readers in making (or not making) specific investment decisions. Penny Sleuth is an unregulated product published by Fleet Street Publications Ltd.
Red Hot Biotech Alert (formerly known as The Bulford Files) is a regulated product issued by Fleet Street Publications Ltd. Your capital is at risk when you invest in shares, never risk more than you can afford to lose. Please seek independent financial advice if necessary. Customer Services: 0207 633 3600.
-
Rail fares could spike by 5.8% next year – how to save on train travelJuly’s RPI inflation reading tends to determine rail fare hikes in the following year. We look at how much your train tickets could cost, and how to save money
-
'Governments are launching an assault on the independence of central banks'Opinion Say goodbye to the era of central bank orthodoxy and hello to the new era of central bank dependency, says Jeremy McKeown
-
Somero: trading this overlooked bargainFeatures Mechanical-screed maker Somero dominates its niche and is attractively valued. Matthew Partridge picks the best way to trade it.
-
How to find big profits in small companiesCover Story The small- and micro-cap sectors are risky and volatile. But with careful research and patience, investors could make huge gains. Matthew Partridge explains how to find the market’s top tiddlers.
-
The hidden gems on Aim, London's junior marketFeatures Aim, London’s junior market, is risky – but you can find solid stocks at low prices. Scott Longley reports.
-
Three Aim-listed firms that will thrive in a post-Brexit worldOpinion Matt Tonge and Victoria Stevens of the Liontrust UK Smaller Companies Fund pick three Aim-listed firms that will survive Brexit turmoil.
-
Fetch! The Chinese small-cap stocks to buy in the Year of the Dog
Opinion Each week, a professional investor tells us where she’d put her money. This week: Tiffany Hsiao of Matthews Asia selects three Chinese small-cap stocks with exciting potential.
-
Small and mid-cap stocks with big potential
Opinion Professional investor Guy Anderson of the Mercantile Investment Trust selects three small and medium-sized firms with promising prospects that the market has missed.
-
Get cheap, reliable growth from smaller companiesFeatures One of the most reliable long-term investment trends is the long-term outperformance of smaller companies over blue chips. Max King picks some of the best ways to buy into this growth.
-
Now the bitcoin bubble’s burst, what’s the next big thing?Features Forget bitcoin, if you want to increase your wealth faster than most other people, you need to find the next big thing. Merryn Somerset Webb suggests some places to look.
